Introduction: liver cancer disease burden: By 2040, the number of confirmed and deadly people around the world will increase by more than 55% every year; virtual drug scans identify potential new antidepressants; Eli Lilly RET inhibitors are approved in China and will benefit specific lung cancer and thyroid cancer patients... Biological Exploration will follow the "drug" news with you and explore the value of biotechnology!
01 By 2040, the number of confirmed liver cancer in the world and deaths will increase by more than 55% each year
Recently, a study released by International Cancer Research Institution (IARC), a subsidiary of World Health Organization , a study released by International Cancer Research Institution (IARC), a subsidiary of , a study showing that by 2040, the number of confirmed liver cancer and deaths in the world every year is expected to increase by more than 55%.
According to the latest evaluation, in 2020, 905,700 people worldwide suffered from liver cancer and 830,200 died of liver cancer; assuming the current incidence and mortality rate remain unchanged, scientists estimate that 1.4 million people may be diagnosed with liver cancer and 1.3 million died of liver cancer by 2040.
liver cancer is the third largest cause of cancer death in the world, but most cases of liver cancer can be prevented. The researchers stressed that these latest forecasts indicate that there is an urgent need to strengthen existing liver cancer prevention measures, such as immunization, testing and treatment for hepatitis B virus infection, as well as testing and treatment for hepatitis C virus infection in the whole population; at the same time, measures should be taken to reduce public alcohol consumption and curb the increase in the incidence of diabetes and obesity. All of these measures can have an impact on reducing the burden of liver cancer.
02 Virtual drug scans identify
potential new antidepressant
Recently, scientists reported that two LSD (lysergic acid diethylamide) analog chemical molecules have antidepressant effects in mice, but have no hallucinogenic side effects. While further testing is needed to determine whether they can be used as candidates for humans, the discovery of these drugs may lead to future drug development for the treatment of mental disorders.
hallucinogens such as LSD and psilocybin are known to target specific serotonin receptors and are considered as alternative treatments for mental disorders such as schizophrenia , depression and anxiety. However, it is not clear whether such therapeutic compounds can be developed without hallucinogenic effects. Developing therapeutic drugs similar to LSD without hallucinogenic effects is an attractive target for the treatment of mental disorders. Virtual screening is a computer method for predicting drug activity that can be used to find interesting compounds targeting serotonin receptors.
03 Eli Lilly RET inhibitor was approved in China.
Hui and specific lung cancer and thyroid cancer patients
On October 8, Eli Lilly announced that its new drug marketing application for its highly selective transfection rearrangement (RET) inhibitor ceprotinib has been approved by the China National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer who are positive for RET gene fusion, advanced or metastatic RET mutant medullary thyroid cancer who require systematic treatment and children with 12 years and above, as well as adults with advanced or metastatic RET fusion positive thyroid cancer who require systematic treatment and who are refractory to treat radioiodine (if radioiodine is applicable). Public information shows that ceptinib is the first precise therapy approved to treat patients with RET gene mutations.
ceptinib is a highly specific, powerful oral RET inhibitor. It can not only inhibit natural RET signaling pathways, but also inhibit possible acquired resistance. In May 2020, the FDA approved the launch of ceptinib to treat patients with non-small cell lung cancer, , myeloid thyroid cancer and thyroid cancer that carry RET gene fusion or mutation.
In November 2021, the Drug Review Center of the State Drug Administration of China accepted the application for the marketing of Seprotinib capsules and included them in the priority review. In March 2022, Eli Lilly and Innovent Biologics further deepened their strategic cooperation in the oncology field, including Innovent Biologics' exclusive commercialization rights of seprotinib in China.
04 USD 400 million! Sanofi cooperates with RNA therapy newcomer
to develop antibody-RNA conjugation drug
On October 4, miRecule announced a strategic cooperation and exclusive license agreement with Sanofi to accelerate the development of antibody-RNA conjugates (ARC) for the treatment of facial shoulder humeral muscular dystrophy (FSHD). The partnership marks the first time miRecule has used its DREAmiR platform to conduct authorized transactions.
According to the agreement, miRecule will grant Sanofi exclusive global license for FSHD therapy. Sanofi will be fully responsible for IND research and global development and commercialization activities. miRecule will first receive an advance payment of approximately US$30 million, and will receive milestone payments totaling nearly US$400 million and tiered royalties and other fees in the future.
FSHD is the second most common type of muscle dystrophy, with more than 1 million patients worldwide, but there are currently no approved treatments. FSHD is caused by a mutation in the DUX4 gene, which causes the patient to experience progressive muscle function deterioration and disability. MC-DX4 can prevent FSHD development by interfering with or reducing DUX4 gene expression in muscle tissue.
05 Hualing Pharmaceutical's first in class antidiabetic drug
"Dogliasetin" was approved for marketing
On October 8, the first in class antidiabetic drug dogliasetin developed by Hualing Pharmaceutical's official approval for marketing was officially approved by NMPA. Dogliasetin is a world's first glucose kinase promoter (GKA), which aims to control the progressive degenerative properties of diabetes by solving the glucose sensing function of glucose kinase (GK). Dogliasetine is expected to become the first-line standard drug for the treatment of type 2 diabetes, which can be used as a single drug or as a basic drug in combination with currently approved antidiabetic drugs.
Organization|Muzijiu
Typeset|Muzijiu
End
